Literature DB >> 24055595

Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans.

Christine A Rabinak1, Mike Angstadt2, Maryssa Lyons2, Shoko Mori2, Mohammed R Milad3, Israel Liberzon2, K Luan Phan4.   

Abstract

Pre-extinction administration of Δ9-tetrahydrocannibinol (THC) facilitates recall of extinction in healthy humans, and evidence from animal studies suggest that this likely occurs via enhancement of the cannabinoid system within the ventromedial prefrontal cortex (vmPFC) and hippocampus (HIPP), brain structures critical to fear extinction. However, the effect of cannabinoids on the underlying neural circuitry of extinction memory recall in humans has not been demonstrated. We conducted a functional magnetic resonance imaging (fMRI) study using a randomized, double-blind, placebo-controlled, between-subjects design (N=14/group) coupled with a standard Pavlovian fear extinction paradigm and an acute pharmacological challenge with oral dronabinol (synthetic THC) in healthy adult volunteers. We examined the effects of THC on vmPFC and HIPP activation when tested for recall of extinction learning 24 h after extinction learning. Compared to subjects who received placebo, participants who received THC showed increased vmPFC and HIPP activation to a previously extinguished conditioned stimulus (CS+E) during extinction memory recall. This study provides the first evidence that pre-extinction administration of THC modulates prefrontal-limbic circuits during fear extinction in humans and prompts future investigation to test if cannabinoid agonists can rescue or correct the impaired behavioral and neural function during extinction recall in patients with PTSD. Ultimately, the cannabinoid system may serve as a promising target for innovative intervention strategies (e.g. pharmacological enhancement of exposure-based therapy) in PTSD and other fear learning-related disorders.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amygdala; Extinction; Hippocampus; Ventromedial prefrontal cortex; fMRI; Δ9-Tetrahydrocannabinol

Mesh:

Substances:

Year:  2013        PMID: 24055595      PMCID: PMC3960373          DOI: 10.1016/j.nlm.2013.09.009

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  76 in total

1.  Activation of the left amygdala to a cognitive representation of fear.

Authors:  E A Phelps; K J O'Connor; J C Gatenby; J C Gore; C Grillon; M Davis
Journal:  Nat Neurosci       Date:  2001-04       Impact factor: 24.884

2.  Three-dimensional tailored RF pulses for the reduction of susceptibility artifacts in T(*)(2)-weighted functional MRI.

Authors:  V A Stenger; F E Boada; D C Noll
Journal:  Magn Reson Med       Date:  2000-10       Impact factor: 4.668

3.  Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.

Authors:  N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot
Journal:  Neuroimage       Date:  2002-01       Impact factor: 6.556

4.  Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function.

Authors:  S Bhattacharyya; Z Atakan; R Martin-Santos; J A Crippa; J Kambeitz; D Prata; S Williams; M Brammer; D A Collier; P K McGuire
Journal:  Mol Psychiatry       Date:  2012-01-31       Impact factor: 15.992

Review 5.  Investigating the pathogenesis of posttraumatic stress disorder with neuroimaging.

Authors:  R K Pitman; L M Shin; S L Rauch
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

6.  De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder.

Authors:  S P Orr; L J Metzger; N B Lasko; M L Macklin; T Peri; R K Pitman
Journal:  J Abnorm Psychol       Date:  2000-05

7.  Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.

Authors:  David L Walker; Kerry J Ressler; Kwok-Tung Lu; Michael Davis
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

Review 8.  Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment.

Authors:  Christopher R Bailey; Elisabeth Cordell; Sean M Sobin; Alexander Neumeister
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

9.  Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.

Authors:  S R Wachtel; M A ElSohly; S A Ross; J Ambre; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  2002-04-19       Impact factor: 4.530

10.  Cannabidiol enhances consolidation of explicit fear extinction in humans.

Authors:  Ravi K Das; Sunjeev K Kamboj; Mayurun Ramadas; Kishoj Yogan; Vivek Gupta; Emily Redman; H Valerie Curran; Celia J A Morgan
Journal:  Psychopharmacology (Berl)       Date:  2013-01-10       Impact factor: 4.530

View more
  44 in total

Review 1.  Neuroimaging of Fear-Associated Learning.

Authors:  John A Greco; Israel Liberzon
Journal:  Neuropsychopharmacology       Date:  2015-08-21       Impact factor: 7.853

2.  Transdiagnostic neural correlates of volitional emotion regulation in anxiety and depression.

Authors:  Jacklynn M Fitzgerald; Heide Klumpp; Scott Langenecker; K Luan Phan
Journal:  Depress Anxiety       Date:  2018-11-08       Impact factor: 6.505

Review 3.  Augmentation of Evidence-Based Psychotherapy for PTSD With Cognitive Enhancers.

Authors:  Marie-France Marin; Sylwia Fowler Lonak; Mohammed R Milad
Journal:  Curr Psychiatry Rep       Date:  2015-06       Impact factor: 5.285

Review 4.  Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.

Authors:  Liana Fattore; Alessandro Piva; Mary Tresa Zanda; Guido Fumagalli; Cristiano Chiamulera
Journal:  Psychopharmacology (Berl)       Date:  2017-11-25       Impact factor: 4.530

Review 5.  Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders.

Authors:  Olena Bukalo; Courtney R Pinard; Andrew Holmes
Journal:  Br J Pharmacol       Date:  2014-07-23       Impact factor: 8.739

Review 6.  Sex differences in fear extinction.

Authors:  E R Velasco; A Florido; M R Milad; R Andero
Journal:  Neurosci Biobehav Rev       Date:  2019-05-23       Impact factor: 8.989

Review 7.  Stress and Fear Extinction.

Authors:  Stephen Maren; Andrew Holmes
Journal:  Neuropsychopharmacology       Date:  2015-06-24       Impact factor: 7.853

Review 8.  Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research.

Authors:  Santiago Papini; Gregory M Sullivan; Denise A Hien; Erel Shvil; Yuval Neria
Journal:  Biol Psychol       Date:  2014-11-04       Impact factor: 3.251

9.  Protective effects of elevated anandamide on stress and fear-related behaviors: translational evidence from humans and mice.

Authors:  Leah M Mayo; Anna Asratian; Johan Lindé; Lovisa Holm; Daniel Nätt; Gaëlle Augier; Niclas Stensson; Haley A Vecchiarelli; Georgia Balsevich; Robert J Aukema; Bijar Ghafouri; Primavera A Spagnolo; Francis S Lee; Matthew N Hill; Markus Heilig
Journal:  Mol Psychiatry       Date:  2018-08-17       Impact factor: 15.992

Review 10.  Developmental regulation of fear learning and anxiety behavior by endocannabinoids.

Authors:  T T-Y Lee; M N Hill; F S Lee
Journal:  Genes Brain Behav       Date:  2015-11-05       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.